The Future of Drug Discovery is 3D

Improving the identification and validation of disease-specific drug targets in a cell-type and patient-specific manner early on will not only reduce the failure rate and cost that is so inherent in current drug development processes but also allow the development of more effective precision medicines, improving patient outcomes. The post The Future of Drug Discovery…

Read More

The Outlook for PEPFAR in 2025 and Beyond

PEPFAR, the U.S. global HIV/AIDS program, is – for the first time in its two-decade history – facing significant challenges that could impede its ability to fulfill its mission. This policy brief provides an overview of recent events and ongoing challenges facing the program.

Read More

Improving the patient experience – why it matters

No matter how much the healthcare industry evolves — whether through new legislative priorities or advances in AI and automation — one thing remains constant: the patient experience matters. Patients expect quality care, quickly. For five years running, timely access has been a top priority for patients, according to Experian Health’s State of Patient Access…

Read More

Recursion Pharma Accelerator Steps In to Fill Some of the Funding Gap Amid NIH Tumult

Altitude Lab Fund will provide pre-seed funding for early-stage startups affected by changes to grant programs administered by the National Institutes of Health. Accepted applicants will be admitted to Altitude Lab, the Salt Lake City biotech accelerator formed by Recursion Pharmaceuticals. The post Recursion Pharma Accelerator Steps In to Fill Some of the Funding Gap…

Read More